Skip to main content

Advertisement

SpringerLink
Log in

Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials

  • Review
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of nosocomial pneumonia. Compared with glycopeptide antibiotics, linezolid achieves higher lung epithelial lining fluid concentrations, which may have an advantage in treating nosocomial pneumonia patients. The objective of this study was to evaluate the efficacy and safety of linezolid versus vancomycin or teicoplanin for the treatment of nosocomial pneumonia. Data were obtained from the Cochrane Central Register of Controlled Trials and the EMBASE and MEDLINE databases. Randomised controlled studies involving the use of linezolid versus vancomycin or teicoplanin in nosocomial pneumonia patients were included in the study. Twelve linezolid trials were included. There was no statistically significant difference between the two groups in the treatment of nosocomial pneumonia regarding the clinical cure rate [relative risk (RR) = 1.08, 95 % confidence interval (CI) = 1.00–1.17, p = 0.06]. Linezolid was associated with better microbiological eradication rate in nosocomial pneumonia patients compared with glycopeptide antibiotics (RR = 1.16, 95 % CI = 1.03–1.31, p = 0.01). There were no differences in the all-cause mortality (RR = 0.95, 95 % CI = 0.83–1.09, p = 0.46) between the two groups. However, the risks of rash (RR = 0.41, 95 % CI = 0.24–0.71, p = 0.001) and renal dysfunction (RR = 0.41, 95 % CI = 0.27–0.64, p < 0.0001) were higher with glycopeptide antibiotics. Although linezolid was more effective in eradicating microbiology than glycopeptide antibiotics for nosocomial pneumonia patients, it did not demonstrate superiority in clinical cure. The incidences of renal dysfunction and rash are higher in the glycopeptide antibiotics group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Emori TG, Gaynes RP (1993) An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 6:428–442

    PubMed  CAS  Google Scholar 

  2. Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867–903

    Article  PubMed  Google Scholar 

  3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309–317

    Article  PubMed  Google Scholar 

  4. Richards MJ, Edwards JR, Culver DH, Gaynes R (2000) Nosocomial infections in combined medical–surgical intensive care units in the United States. Infect Control Hosp Epidemiol 21:510–515

    Article  PubMed  CAS  Google Scholar 

  5. Fridkin SK, Hill HA, Volkova NV, Edwards JR, Lawton RM, Gaynes RP, McGowan JE Jr; Intensive Care Antimicrobial Resistance Epidemiology Project Hospitals (2002) Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 8:697–701

    Google Scholar 

  6. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA; EMERGEncy ID Net Study Group (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666–674

    Article  PubMed  CAS  Google Scholar 

  7. Wang F, Zhu DM, Hu FP, Zhang YY (2001) Surveillance of bacterial resistance among isolates in Shanghai in 1999. J Infect Chemother 7:117–120

    Article  PubMed  CAS  Google Scholar 

  8. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS (2005) Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 128:3854–3862

    Article  PubMed  Google Scholar 

  9. DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS (2005) Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 128:1414–1422

    Article  PubMed  Google Scholar 

  10. González C, Rubio M, Romero-Vivas J, González M, Picazo JJ (1999) Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 29:1171–1177

    Article  PubMed  Google Scholar 

  11. Wong SS, Ng TK, Yam WC, Tsang DN, Woo PC, Fung SK, Yuen KY (2000) Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 36:261–268

    Article  PubMed  CAS  Google Scholar 

  12. Stevens DL, Dotter B, Madaras-Kelly K (2004) A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2:51–59

    Article  PubMed  CAS  Google Scholar 

  13. Conte JE Jr, Golden JA, Kipps J, Zurlinden E (2002) Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 46:1475–1480

    Article  PubMed  CAS  Google Scholar 

  14. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789–1797

    Article  PubMed  CAS  Google Scholar 

  15. American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416

    Article  Google Scholar 

  16. Powers JH, Ross DB, Lin D, Soreth J (2004) Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 126:314–316

    Article  PubMed  Google Scholar 

  17. Kalil AC, Puumala SE, Stoner J (2004) Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest 125:2370–2371

    Article  PubMed  Google Scholar 

  18. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun JF, Rupp ME (2010) Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 38:1802–1808

    Article  PubMed  CAS  Google Scholar 

  19. Walkey AJ, O’Donnell MR, Wiener RS (2011) Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 139:1148–1155

    Article  PubMed  CAS  Google Scholar 

  20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12

    Article  PubMed  CAS  Google Scholar 

  21. Wilcox M, Nathwani D, Dryden M (2004) Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 53:335–344

    Article  PubMed  CAS  Google Scholar 

  22. Wunderink RG, Mendelson MH, Somero MS, Fabian TC, May AK, Bhattacharyya H, Leeper KV Jr, Solomkin JS (2008) Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 134:1200–1207

    Article  PubMed  CAS  Google Scholar 

  23. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, Niki Y, Watanabe S, Furue M, Ito T, Croos-Dabrera R, Tack KJ (2007) Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 60:1361–1369

    Article  PubMed  CAS  Google Scholar 

  24. Lin DF, Zhang YY, Wu JF, Wang F, Zheng JC, Miao JZ, Zheng LY, Sheng RY, Zhou X, Shen HH, Ijzerman MM, Croos-Dabrera RV, Sheng W (2008) Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents 32:241–249

    Article  PubMed  CAS  Google Scholar 

  25. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481–1490

    Article  PubMed  CAS  Google Scholar 

  26. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid Nosocomial Pneumonia Study Group (2003) Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 25:980–992

    Article  PubMed  CAS  Google Scholar 

  27. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ (2006) Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42:597–607

    Article  PubMed  CAS  Google Scholar 

  28. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB (2003) Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates. Pediatr Infect Dis J 22:S158–S163

    Article  PubMed  Google Scholar 

  29. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB; Linezolid Pediatric Study Group (2003) Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 22:677–686

    Article  PubMed  Google Scholar 

  30. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group (2001) Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32:402–412

    Article  PubMed  CAS  Google Scholar 

  31. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, Taylor L, Hayman S, Shaw S, Kibbler C, Shulman R, Singer M, Wilson AP (2004) Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 53:345–355

    Article  PubMed  CAS  Google Scholar 

  32. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54:621–629

    Article  PubMed  CAS  Google Scholar 

  33. Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B (2005) Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 33:1529–1533

    Article  PubMed  CAS  Google Scholar 

  34. Boselli E, Breilh D, Caillault-Sergent A, Djabarouti S, Guillaume C, Xuereb F, Bouvet L, Rimmelé T, Saux MC, Allaouchiche B (2012) Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother 67:1207–1210

    Article  PubMed  CAS  Google Scholar 

  35. Yoshizawa S, Tateda K, Saga T, Ishii Y, Yamaguchi K (2012) Virulence-suppressing effects of linezolid on methicillin-resistant Staphylococcus aureus: possible contribution to early defervescence. Antimicrob Agents Chemother 56:1744–1748

    Article  PubMed  CAS  Google Scholar 

  36. Falagas ME, Siempos II, Vardakas KZ (2008) Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8:53–66

    Article  PubMed  CAS  Google Scholar 

  37. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W (2010) Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 35:3–12

    Article  PubMed  Google Scholar 

  38. Kuter DJ, Tillotson GS (2001) Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 21:1010–1013

    Article  PubMed  CAS  Google Scholar 

  39. Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, Pichardo C, Ibáñez-Martínez J, Pachón J (2012) Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 67:1961–1967

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Natural Science Foundation of Jiangsu Province (no. BK 2011603) and the Foundation of Southeast University (no. seucx 201107).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Geriatric Oncology, The Second Affiliated Hospital, Southeast University, 1-1 Zhongfu Street, Nanjing, Jiangsu, 210003, People’s Republic of China

    H. Jiang

  2. Institute of Nephrology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, People’s Republic of China

    R.-N. Tang

  3. Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210008, People’s Republic of China

    J. Wang

Authors
  1. H. Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R.-N. Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Jiang.

Additional information

H. Jiang and R.-N. Tang contribute equally to this article and should be considered as co-first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jiang, H., Tang, RN. & Wang, J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis 32, 1121–1128 (2013). https://doi.org/10.1007/s10096-013-1867-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-013-1867-z

Keywords

Search

Navigation